- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Discussing Increased Prevalence of NAFLD and NASH, and the Current Lack of Treatments
Despite how common nonalcoholic fatty liver disease is, there are currently no approved medications on the market. Instead, patients have to rely on lifestyle modification, such as weight loss, increased physical activity, and dietary changes. However, that may change.
One of the most common causes of liver disease in the United States is nonalcoholic fatty liver disease (NAFLD), affecting between 30% and 40% of adults, according to the National Institute of Diabetes, and Digestive and Kidney Diseases. It’s a condition in which excess fat is stored in the liver—a buildup that is not caused by heavy alcohol use.
Despite how common NAFLD is, there are currently no approved medications on the market. In this podcast, we talk to a clinician involved with a program that uses lifestyle management and a patient advocate, who is trying to shape policy to help patients with NAFLD and its more extreme version, nonalcoholic steatohepatitis (NASH).
To listen, login to the website.
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
Listen above or through one of these podcast services:
Read more about NAFLD and NASH:
Studies Point to Empagliflozin as First Choice for Fatty Liver Disease in T2D
Drug Approvals That Dr Aimee Tharaldson Is Keeping an Eye on for 2019
Analyzing the Near-Term Pipeline for Specialty Drugs
Dr Aimee Tharaldson: We're Keeping an Eye on Future NASH Treatments
FDA Approves Resmetirom, First Treatment for NASH With Liver Fibrosis
March 14th 2024The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was implementing lifestyle changes aimed at weight reduction.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Pathological Neutrophil Migration in Cirrhosis Linked to Increased Risk of AEs
November 30th 2022A more-developed version of the assay used in this study may help manage patients with acute decompensation of liver cirrhosis or acute-on-chronic liver failure before liver transplantation.
Read More
